CSIMarket
 
Avenue Therapeutics Inc   (ATXI)
Other Ticker:  
 
 
Price: $0.1575 $0.01 3.823%
Day's High: $0.16 Week Perf: 7.14 %
Day's Low: $ 0.15 30 Day Perf: 6.42 %
Volume (M): 1,122 52 Wk High: $ 1.36
Volume (M$): $ 177 52 Wk Avg: $0.70
Open: $0.15 52 Wk Low: $0.11



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -11
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Avenue Therapeutics Inc
Avenue Therapeutics Inc. is a pharmaceutical company focused on the development and commercialization of an intravenous (IV) form of an opioid pain medication called Tramadol. Tramadol is commonly used to manage moderate to severe pain, and Avenue Therapeutics aims to provide a potentially safer and more effective alternative to existing IV pain medications. The company is dedicated to improving patient care and addressing the opioid crisis by offering a non-addictive solution for acute pain relief. Avenue Therapeutics is based in New York City, and it is a subsidiary of InvaGen Pharmaceuticals, a global pharmaceutical company.


   Company Address: 1111 Kane Concourse, Suite 301 Bay Harbor Islands 33154 FL
   Company Phone Number: 652?4500   Stock Exchange / Ticker: NASDAQ ATXI
   ATXI is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

Avenue Therapeutics Makes Breakthrough in Absence Epilepsy Treatment, Despite Financial Setback

Published Thu, Feb 22 2024 1:30 PM UTC



In an exciting development for the healthcare industry, Avenue Therapeutics has recently published a groundbreaking study showcasing the preclinical data of their first-in-class drug, BAER-101, in the treatment of absence epilepsy. The drug has demonstrated a unique ability to significantly suppress seizures in a translational model of absence epilepsy, utilizing t...

Management Announcement

Avenue Therapeutics Secures $5 Million in Proceeds through Warrant Exercise to Fuel Neurologic Disease Therapies

Published Fri, Jan 5 2024 2:15 PM UTC

Avenue Therapeutics Raises $5 Million in Proceeds through Warrant Exercise Transactions
Miami, January 5, 2024 - Avenue Therapeutics, a specialty pharmaceutical company specializing in the development and commercialization of therapies for neurologic diseases, has announced its entry into warrant exercise agreements with existing accredited investors. Under these agreem...

Clinical Study

FDA Greenlights Avenue Therapeutics' Phase 3 Protocol for IV Tramadol in Landmark Agreement

Published Thu, Jan 4 2024 1:31 PM UTC

Avenue Therapeutics' Landmark Agreement with FDA for Phase 3 Safety Protocol on IV TramadolAvenue Therapeutics, Inc. (Nasdaq: ATXI), a niche pharmaceutical firm specializing in the development and commercialization of treatments for neurological disorders, has recently announced achieving a final agreement with the US Food and Drug Administration (FDA) regarding the Phase 3 ...

Clinical Study

Avenue Therapeutics' Milestone Trial Advances Potential Treatment for Kennedy's Disease

Published Tue, Jan 2 2024 1:31 PM UTC

Avenue Therapeutics Reaches Milestone in Clinical Trial for Treating Spinal and Bulbar Muscular AtrophyAvenue Therapeutics Inc, a leading biopharmaceutical company, recently announced the completion of patient enrollment in their Phase 1b/2a clinical trial for the investigational drug AJ201. Developed specifically for treating Spinal and Bulbar Muscular Atrophy, also known a...

Avenue Therapeutics Inc

Avenue Therapeutics Inc Boosts Growth with Surging Working Expenditures in Q3 2023

The stock market has been buzzing with excitement as numerous corporations release their fiscal earnings for the third quarter of 2023. One sector that has captured investors' attention is the Major Pharmaceutical Preparations sector, and among its constituents is Avenue Therapeutics Inc (ATXI). While the company has reported an operating shortfall of $-2.068 million for this quarter, there are positive indications of growth and potential.
To put this latest effort into perspective, we can look back at Avenue Therapeutics' performance during the third quarter of 2022. During that period, the company reported an operating shortfall of $-0.663 million. It's clear that the company has made significant progress, as the numbers show a surplus in the third quarter of 2023. Furthermore, the net profit has improved from $-0.662 million in 2022 to $0.513 million this year. These numbers demonstrate Avenue Therapeutics' dedication to increasing its profitability and creating value for shareholders.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com